IL124279A - Transdermal therapeutic systems containing hmg-coa reductase inhibitors - Google Patents
Transdermal therapeutic systems containing hmg-coa reductase inhibitorsInfo
- Publication number
- IL124279A IL124279A IL12427997A IL12427996A IL124279A IL 124279 A IL124279 A IL 124279A IL 12427997 A IL12427997 A IL 12427997A IL 12427996 A IL12427996 A IL 12427996A IL 124279 A IL124279 A IL 124279A
- Authority
- IL
- Israel
- Prior art keywords
- coa reductase
- reductase inhibitors
- transdermal therapeutic
- systems containing
- therapeutic systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19541260A DE19541260A1 (de) | 1995-11-06 | 1995-11-06 | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
PCT/EP1996/004138 WO1997017061A1 (de) | 1995-11-06 | 1996-09-21 | Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut |
Publications (1)
Publication Number | Publication Date |
---|---|
IL124279A true IL124279A (en) | 2003-07-06 |
Family
ID=7776710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12427997A IL124279A (en) | 1995-11-06 | 1996-09-21 | Transdermal therapeutic systems containing hmg-coa reductase inhibitors |
Country Status (21)
Country | Link |
---|---|
US (1) | US6379696B1 (es) |
EP (1) | EP0859595B1 (es) |
JP (1) | JP2001507331A (es) |
KR (1) | KR100445940B1 (es) |
CN (1) | CN1201385A (es) |
AT (1) | ATE186209T1 (es) |
AU (1) | AU716896B2 (es) |
CZ (1) | CZ289143B6 (es) |
DE (2) | DE19541260A1 (es) |
ES (1) | ES2141534T3 (es) |
GR (1) | GR3032523T3 (es) |
IL (1) | IL124279A (es) |
MX (1) | MX9803563A (es) |
MY (1) | MY132407A (es) |
NO (1) | NO982006L (es) |
NZ (1) | NZ318783A (es) |
PL (1) | PL326497A1 (es) |
PT (1) | PT859595E (es) |
SK (1) | SK281405B6 (es) |
WO (1) | WO1997017061A1 (es) |
ZA (1) | ZA969271B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19830732B4 (de) * | 1998-07-09 | 2008-11-13 | Lts Lohmann Therapie-Systeme Ag | Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung |
EP1335711B1 (en) * | 2000-09-08 | 2007-07-25 | Alza Corporation | Transdermal device |
US20020187169A1 (en) * | 2001-05-11 | 2002-12-12 | Shoujun Chen | Kavalactone compositions |
US7323191B2 (en) * | 2003-07-28 | 2008-01-29 | Alza Corporation | Transdermal warfarin system |
EP1731147A4 (en) * | 2004-03-31 | 2010-06-30 | Kowa Co | EXTERNAL PREPARATION |
WO2007125339A1 (en) | 2006-04-26 | 2007-11-08 | Rosemont Pharmaceuticals Ltd | Liquid oral compositions |
JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
US7652767B2 (en) * | 2006-10-19 | 2010-01-26 | Sporian Microsystems, Inc. | Optical sensor with chemically reactive surface |
US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
RU2492175C2 (ru) | 2007-04-02 | 2013-09-10 | Теракос, Инк. | Бензиловые производные гликозидов и способы их применения |
EP2187742B1 (en) | 2007-08-23 | 2017-10-25 | Theracos Sub, LLC | (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes |
TWI523652B (zh) | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
CN105237502A (zh) | 2008-08-22 | 2016-01-13 | 泰拉科斯萨伯有限责任公司 | 制备sglt2抑制剂的方法 |
ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
EP2445506B1 (en) | 2009-06-24 | 2014-12-31 | Entarco SA | The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer |
CN103491778B (zh) | 2010-04-13 | 2017-05-31 | 雷尔玛达治疗股份有限公司 | 1‑甲基‑n‑(2,6‑二甲苯基)‑2‑哌啶甲酰胺的皮肤用药物组合物及其使用方法 |
WO2011149950A2 (en) | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
EP2654757A1 (en) | 2010-12-22 | 2013-10-30 | Entarco SA | The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents |
WO2012112933A1 (en) | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
US9420820B2 (en) | 2013-08-09 | 2016-08-23 | University Of Tsukuba | Method for isolating polyphenols from olive mill water |
EP3119394B1 (en) | 2014-03-19 | 2021-05-12 | Curza Global LLC | Compositions and methods comprising 2-(acylamino)imidazoles |
JP2020512981A (ja) | 2017-03-31 | 2020-04-30 | カーザ グローバル,リミティド ライアビリティ カンパニー | 置換2−アミノイミダゾールを含む組成物と方法 |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
JP2023548538A (ja) | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | 併用療法 |
JP2024514816A (ja) | 2021-04-09 | 2024-04-03 | シージェン インコーポレイテッド | 抗tigit抗体を用いるがんの治療方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
US5211947A (en) * | 1988-12-16 | 1993-05-18 | Schering Corporation | Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
WO1991015241A1 (en) * | 1990-03-30 | 1991-10-17 | Yasunori Morimoto | Percutaneously absorbable composition of narcotic and nonnarcotic analgesics |
IL109037A (en) * | 1993-03-19 | 1999-01-26 | Cellegy Pharma Inc | Preparations for causing phase separation of lipid layers and preparation of the above preparations |
DE4341444C2 (de) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
-
1995
- 1995-11-06 DE DE19541260A patent/DE19541260A1/de not_active Withdrawn
-
1996
- 1996-09-21 JP JP51777797A patent/JP2001507331A/ja active Pending
- 1996-09-21 IL IL12427997A patent/IL124279A/xx not_active IP Right Cessation
- 1996-09-21 AU AU70859/96A patent/AU716896B2/en not_active Ceased
- 1996-09-21 CN CN96198113A patent/CN1201385A/zh active Pending
- 1996-09-21 EP EP96931820A patent/EP0859595B1/de not_active Expired - Lifetime
- 1996-09-21 PT PT96931820T patent/PT859595E/pt unknown
- 1996-09-21 WO PCT/EP1996/004138 patent/WO1997017061A1/de active IP Right Grant
- 1996-09-21 NZ NZ318783A patent/NZ318783A/en unknown
- 1996-09-21 US US09/068,326 patent/US6379696B1/en not_active Expired - Lifetime
- 1996-09-21 KR KR10-1998-0703316A patent/KR100445940B1/ko not_active IP Right Cessation
- 1996-09-21 DE DE59603597T patent/DE59603597D1/de not_active Expired - Lifetime
- 1996-09-21 SK SK558-98A patent/SK281405B6/sk unknown
- 1996-09-21 PL PL96326497A patent/PL326497A1/xx unknown
- 1996-09-21 AT AT96931820T patent/ATE186209T1/de active
- 1996-09-21 CZ CZ19981366A patent/CZ289143B6/cs not_active IP Right Cessation
- 1996-09-21 ES ES96931820T patent/ES2141534T3/es not_active Expired - Lifetime
- 1996-11-04 MY MYPI96004590A patent/MY132407A/en unknown
- 1996-11-05 ZA ZA969271A patent/ZA969271B/xx unknown
-
1998
- 1998-05-04 NO NO982006A patent/NO982006L/no not_active Application Discontinuation
- 1998-05-06 MX MX9803563A patent/MX9803563A/es not_active IP Right Cessation
-
2000
- 2000-01-31 GR GR20000400219T patent/GR3032523T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1201385A (zh) | 1998-12-09 |
SK55898A3 (en) | 1998-11-04 |
KR19990067320A (ko) | 1999-08-16 |
SK281405B6 (sk) | 2001-03-12 |
EP0859595B1 (de) | 1999-11-03 |
CZ136698A3 (cs) | 1998-07-15 |
NZ318783A (en) | 1999-04-29 |
NO982006D0 (no) | 1998-05-04 |
NO982006L (no) | 1998-05-04 |
PL326497A1 (en) | 1998-09-28 |
MX9803563A (es) | 1998-09-30 |
WO1997017061A1 (de) | 1997-05-15 |
ES2141534T3 (es) | 2000-03-16 |
DE59603597D1 (de) | 1999-12-09 |
JP2001507331A (ja) | 2001-06-05 |
KR100445940B1 (ko) | 2005-09-30 |
PT859595E (pt) | 2000-04-28 |
MY132407A (en) | 2007-10-31 |
ATE186209T1 (de) | 1999-11-15 |
US6379696B1 (en) | 2002-04-30 |
GR3032523T3 (en) | 2000-05-31 |
ZA969271B (en) | 1997-06-03 |
AU7085996A (en) | 1997-05-29 |
CZ289143B6 (cs) | 2001-11-14 |
DE19541260A1 (de) | 1997-05-07 |
AU716896B2 (en) | 2000-03-09 |
EP0859595A1 (de) | 1998-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL124279A (en) | Transdermal therapeutic systems containing hmg-coa reductase inhibitors | |
EP0316065A3 (en) | Improved transdermal drug delivery device | |
IE820296L (en) | Dosage form for coadministering a drug and a percutaneous¹absorption enhancer | |
AU4923500A (en) | Device and method for increasing the transdermal permeation of medicaments | |
AU533491B2 (en) | Bandage for administering drugs to the skin | |
WO1997009973A3 (en) | Peripherally active anti-hyperalgesic opiates | |
IE46069L (en) | Adhesive skin patch | |
IL136042A0 (en) | An alcohol-containing composition for topical application | |
DE69532751D1 (de) | Kosmetische, pharmazeutische oder dermatologische Zusammensetzung, sowie die Zusammensetzung Alpha-TNFAntagonisten enthaltend | |
MX9602656A (es) | Dispositivo transdermico que contiene pirrolidona polivinilica como mejorador de solubilidad. | |
HUT72964A (en) | Transdermal therapeutic systems containing crystallization inhibitors | |
BR0215102A (pt) | Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação | |
IL106512A (en) | Plaster for the transdermal application of steroid hormones and process for the preparation thereof | |
DE69731882D1 (de) | Transdermal verabreichtes dextromethorphan als hustenmittel | |
TWI256892B (en) | Plasminogen activator inhibitor and external preparation for skin comprising the same | |
MX9701968A (es) | Emplasto de escopolamina. | |
AU5323398A (en) | Contour of a transdermal therapeutic system | |
NZ509215A (en) | Transdermal plaster preparation containing at least one active ingredient which influences blood serum lipid levels | |
EP0693479A4 (en) | NEW COMPOSITION OF THE ACONITINE TYPE, ANTIPYRETIC, ANALGESIC AND ANTI-INFLAMMATORY AGENT | |
AU715763B2 (en) | Surface-stabilised pharmaceutical preparation for skin application | |
CA2235617A1 (en) | Therapeutic preparation for the transdermal administration of active substances | |
WO2001041771A3 (de) | Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne | |
EP0097953A3 (en) | Synergistic compositions of nalbuphine and non-narcotic analgesic compounds | |
PL332035A1 (en) | Transdermal therapeutic system including an estriol-containing composition of active substances | |
AU1290797A (en) | Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |